Indomethacin Increases Severity of Clostridium Difficile Infection in Mouse Model

Overview

Journal Future Microbiol

Specialties Infectious Diseases
Microbiology

Date 2018 Sep 22

PMID 30238771

Citations 15

Authors

Juan Munoz-Miralles

Bruno C Trindade

Pablo Castro-Cordova

Ingrid L Bergin

Leslie A Kirk

Fernando Gil

David M Aronoff

Daniel Paredes-Sabja

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the effect on the nonsteroidal anti-inflammatory drug indomethacin on Clostridium difficile infection (CDI) severity.

Materials & Methods: Indomethacin was administered in two different mouse models of antibiotic-associated CDI in two different facilities, using a low and high dose of indomethacin.

Results: Indomethacin administration caused weight loss, increased the signs of severe infection and worsened histopathological damage, leading to 100% mortality during CDI. Indomethacin-treated, antibiotic-exposed mice infected with C. difficile had enhanced intestinal inflammation with increased expression of KC, IL-1β and IL-22 compared with infected mice unexposed to indomethacin.

Conclusion: These results demonstrate a negative impact of nonsteroidal anti-inflammatory drugs on antibiotic-associated CDI in mice and suggest that targeting the synthesis or signaling of prostaglandins might be an approach to ameliorating the severity of CDI.

Citing Articles

Integrated analysis of gut metabolome, microbiome, and exfoliome data in an equine model of intestinal injury.

Whitfield-Cargile C, Chung H, Coleman M, Cohen N, Chamoun-Emanuelli A, Ivanov I Microbiome. 2024; 12(1):74.

PMID: 38622632 PMC: 11017594. DOI: 10.1186/s40168-024-01785-1.

Comparison between Symptomatic and Asymptomatic Mice after Infection Reveals Novel Inflammatory Pathways and Contributing Microbiota.

Abdelkhalek A, Narayanan S Microorganisms. 2022; 10(12).

PMID: 36557633 PMC: 9782979. DOI: 10.3390/microorganisms10122380.

How Does COVID-19 Pandemic Impact on Incidence of Infection and Exacerbation of Its Gastrointestinal Symptoms?.

Azimirad M, Noori M, Raeisi H, Yadegar A, Shahrokh S, Aghdaei H Front Med (Lausanne). 2021; 8:775063.

PMID: 34966759 PMC: 8710593. DOI: 10.3389/fmed.2021.775063.

Pain killers: the interplay between nonsteroidal anti-inflammatory drugs and Clostridioides difficile infection.

Soto Ocana J, Bayard N, Zackular J Curr Opin Microbiol. 2021; 65:167-174.

PMID: 34894543 PMC: 9058983. DOI: 10.1016/j.mib.2021.11.011.

Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations.

Kociolek L, Zackular J, Savidge T J Pediatric Infect Dis Soc. 2021; 10(Supplement_3):S8-S15.

PMID: 34791392 PMC: 8600028. DOI: 10.1093/jpids/piab089.

References

Morton D, Griffiths P . Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet Rec. 1985; 116(16):431-6. DOI: 10.1136/vr.116.16.431. View

Gentric A, Pennec Y . Diclofenac-induced pseudomembranous colitis. Lancet. 1992; 340(8811):126-7. DOI: 10.1016/0140-6736(92)90459-g. View

Stewart T, Hetenyi C, Rowsell H, Orizaga M . Ulcerative enterocolitis in dogs induced by drugs. J Pathol. 1980; 131(4):363-78. DOI: 10.1002/path.1711310408. View

Theriot C, Koumpouras C, Carlson P, Bergin I, Aronoff D, Young V . Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes. 2011; 2(6):326-34. PMC: 3337121. DOI: 10.4161/gmic.19142. View

Goldenberg S . Hidden burden of undiagnosed Clostridium difficile infection. Lancet Infect Dis. 2014; 14(12):1167-8. DOI: 10.1016/S1473-3099(14)71010-2. View

Faucheron J, Parc R . Non-steroidal anti-inflammatory drug-induced colitis. Int J Colorectal Dis. 1996; 11(2):99-101. DOI: 10.1007/BF00342469. View

Pepin J, Valiquette L, Cossette B . Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005; 173(9):1037-42. PMC: 1266326. DOI: 10.1503/cmaj.050978. View

Zackular J, Moore J, Jordan A, Juttukonda L, Noto M, Nicholson M . Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection. Nat Med. 2016; 22(11):1330-1334. PMC: 5101143. DOI: 10.1038/nm.4174. View

Pizarro-Guajardo M, Diaz-Gonzalez F, Alvarez-Lobos M, Paredes-Sabja D . Characterization of Chicken IgY Specific to R20291 Spores and the Effect of Oral Administration in Mouse Models of Initiation and Recurrent Disease. Front Cell Infect Microbiol. 2017; 7:365. PMC: 5557795. DOI: 10.3389/fcimb.2017.00365. View

10.

Fowler T, Durham C, Planton J, Edlund B . Use of nonsteroidal anti-inflammatory drugs in the older adult. J Am Assoc Nurse Pract. 2014; 26(8):414-423. DOI: 10.1002/2327-6924.12139. View

11.

Shivashankar R, Khanna S, Kammer P, Harmsen W, Zinsmeister A, Baddour L . Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013; 11(11):1466-71. PMC: 3846768. DOI: 10.1016/j.cgh.2013.04.050. View

12.

Regnault H, Bourrier A, Lalande V, Nion-Larmurier I, Sokol H, Seksik P . Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. Dig Liver Dis. 2014; 46(12):1086-92. DOI: 10.1016/j.dld.2014.09.003. View

13.

Coutrot S, Roland D, Barbier J, Van der Marcq P, Alcalay M, Matuchansky C . Acute perforation of colonic diverticula associated with short-term indomethacin. Lancet. 1978; 2(8098):1055-6. DOI: 10.1016/s0140-6736(78)92385-1. View

14.

Walter T, Chau T, Weichman B . Effects of analgesics on bradykinin-induced writhing in mice presensitized with PGE2. Agents Actions. 1989; 27(3-4):375-7. DOI: 10.1007/BF01972826. View

15.

Suissa D, Delaney J, Dial S, Brassard P . Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated disease. Br J Clin Pharmacol. 2012; 74(2):370-5. PMC: 3630757. DOI: 10.1111/j.1365-2125.2012.04191.x. View

16.

Soes L, Holt H, Bottiger B, Nielsen H, Andreasen V, Kemp M . Risk factors for Clostridium difficile infection in the community: a case-control study in patients in general practice, Denmark, 2009-2011. Epidemiol Infect. 2013; 142(7):1437-48. PMC: 9151208. DOI: 10.1017/S0950268813002380. View

17.

Zhou Y, Boudreau D, Freedman A . Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2013; 23(1):43-50. DOI: 10.1002/pds.3463. View

18.

He M, Miyajima F, Roberts P, Ellison L, Pickard D, Martin M . Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2012; 45(1):109-13. PMC: 3605770. DOI: 10.1038/ng.2478. View

19.

Rogers M, Greene M, Saint S, Chenoweth C, Malani P, Trivedi I . Higher rates of Clostridium difficile infection among smokers. PLoS One. 2012; 7(7):e42091. PMC: 3407081. DOI: 10.1371/journal.pone.0042091. View

20.

Loh A, Ong L, Liew W, Arkachaisri T, Lee V, Narasimhan K . Multiple indomethacin-induced colonic perforations in an adolescent. Singapore Med J. 2011; 52(4):e82-4. View